233 related articles for article (PubMed ID: 33397657)
1. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
Harasymowycz P; Royer C; Cui AX; Barbeau M; Jobin-Gervais K; Mathurin K; Lachaine J; Beauchemin C
Br J Ophthalmol; 2022 May; 106(5):640-647. PubMed ID: 33397657
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
3. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
4. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
[TBL] [Abstract][Full Text] [Related]
5. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
6. Comparing the efficacy of latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%), and timolol (0.5%) in the treatment of primary open angle glaucoma.
Mishra D; Sinha BP; Kumar MS
Korean J Ophthalmol; 2014 Oct; 28(5):399-407. PubMed ID: 25276082
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of medical intervention for normal tension glaucoma.
Cheng JW; Cai JP; Wei RL
Ophthalmology; 2009 Jul; 116(7):1243-9. PubMed ID: 19450880
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T; Lindsley K; Rouse B; Hong H; Shi Q; Friedman DS; Wormald R; Dickersin K
Ophthalmology; 2016 Jan; 123(1):129-40. PubMed ID: 26526633
[TBL] [Abstract][Full Text] [Related]
10. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
11. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
Fingeret M; Gaddie IB; Bloomenstein M
Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
13. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
15. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
[TBL] [Abstract][Full Text] [Related]
16. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
[TBL] [Abstract][Full Text] [Related]
17. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
18. Effect of prophylactic intraocular pressure-lowering medication on pain during cataract surgery.
Ulaş F; Balbaba M; Çelebi S
J Ocul Pharmacol Ther; 2013 Sep; 29(7):658-62. PubMed ID: 23461283
[TBL] [Abstract][Full Text] [Related]
19. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]